Phaseline

Targets › PRAME

PRAME (Melanoma antigen preferentially expressed in tumors): drug programs, companies and trials

8 programs from 7 companies in 13 trials: 11 Phase 1, 2 Phase 3; Oncology; next expected readout Nov 2026.

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation. The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding. (UniProt, P78395)

Open in Phaseline: the race on PRAME, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunocoreBrenetafusp (IMC-F106C)
Immune-mobilizing monoclonal T cell receptor (ImmTAC) targeting PRAME-positive cancer cell
PRAMEPhase 3Advanced Melanoma; Select Advanced Solid TumorsOct 2027
Immatics USIMA203 (anzutresgene autoleucel, anzu-cel)
PRAME-redirected CAR-T cell therapy
PRAMEPhase 3Melanoma, Cutaneous Malignant; Refractory Cancer; Cutaneous MelanomaJan 2028
Catherine BollardTumor associated antigen lymphocytes (TAA-T)
Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN
WT1, PRAME, SURVIVINPhase 1Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain TumorNov 2026
M.D. Anderson Cancer CenterPRAME-TCR-NK cells
PRAME-specific T cell receptor (TCR) engineered natural killer cells
PRAMEPhase 1Lymphodepleting Chemotherapy; Phase 1Apr 2027
ImmunocoreIMC-P115C
Half-life extended (HLE) ImmTAC targeting PRAME; engages T cells to recognize PRAME-presen
PRAMEPhase 1PRAME PositiveSep 2027
Neowise BiotechnologyNW-101C
PRAME-targeted TCR-engineered T cells
PRAMEPhase 1Solid Metastatic TumorDec 2028
Children's National Research InstituteDNR-PRAME Tumor Antigen-specific T cells
PRAME-specific T cells with dTβRII co-stimulation
PRAMEPhase 1RhabdomyosarcomaDec 2041
PDC*line Pharma SASPDC*lung01
Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1,
PRAME, MAGEA3, MAGEA4Phase 1Non Small Cell Lung Cancer–

Conditions

Advanced Melanoma (1) Select Advanced Solid Tumors (1) Solid Metastatic Tumor (1) Lymphodepleting Chemotherapy (1) Phase 1 (1) Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1) Non Small Cell Lung Cancer (1) Melanoma, Cutaneous Malignant (1) Refractory Cancer (1) Cutaneous Melanoma (1) PRAME Positive (1)

Modalities

mixed (3), protein or peptide (2), small molecule (2), other (1)

Companies

Immunocore (2) Neowise Biotechnology (1) M.D. Anderson Cancer Center (1) Catherine Bollard (1) PDC*line Pharma SAS (1) Immatics US (1) Children's National Research Institute (1)

Related targets

WT1 (1) SURVIVIN (1) MAGEA3 (1) MAGEA4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.